News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase II
Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof Of Concept In Second Neuropathic Pain Study In Lumbosacral Radiculopathy 9/23/2014
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014
Invion Limited Provides Update To U.S. FDA On Phase II Study Of Nadolol In Mild Asthma (NIMA) 9/23/2014
Galmed Pharmaceuticals Announces U.S. FDA Approval Of Fast Track Designation Of Aramchol For The Treatment Of NASH 9/23/2014
Gilead Sciences, Inc. (GILD)'s Experimental Drug Simtuzumab Fails Mid-Stage Study 9/22/2014
FibroGen, Inc.Announces One-Year Data Supporting The Safety And Efficacy Profile Of FG-3019 In Patients With Idiopathic Pulmonary Fibrosis 9/22/2014
DBV Technologies Announces Primary Endpoint Met In VIPES, Viaskin Peanut's Phase 2b Clinical Trial In Peanut Allergy 9/22/2014
AbbVie (ABBV) To Present Clinical Study Data On Potential New Oncology Medicines At The 2014 European Society Of Medical Oncology Annual Meeting 9/22/2014
Bio Blast Pharma Announces Initiation Of Its Canadian OPMD Clinical Study Center At McGill University, Montreal 9/22/2014
Progenics Pharmaceuticals, Inc. (PGNX) Presents Long Term Follow-Up Of Pivotal Phase 2 Trial Of Azedra In Malignant Pheochromocytoma 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS - Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – Phase II Trial Results Published In The Leading Medical Journal Neurology 9/22/2014
Flexion Therapeutics (FLXN) Reports FDA Clinical Hold For Phase 2b Trial Of Osteoarthritis Drug 9/19/2014
Umecrine Mood Announces Positive Results From An Exploratory Phase I/II Study With UC1010 In Premenstrual Dysphoric Disorder (PMDD) 9/19/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Paediatric Patients With Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements In Growth And Physical Function 9/19/2014
OXiGENE (OXGN) Initiates Phase 2 Study Of Fosbretabulin In Gastrointestinal Neuroendocrine Tumors 9/18/2014
Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer 9/18/2014
ProSensa Holding N.V. (RNA) Announces Commencement Of Re-Dosing Of Drisapersen In North America In Patients With Duchenne Muscular Dystrophy 9/18/2014
Rebiotix Release: PUNCH CD Study Drug Targeting Recurrent C. Difficile Infection To Be Presented At IDWeek 2014 9/18/2014
Immune Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial In Ulcerative Colitis 9/18/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX (CCH) Data From MULTICORD And Retreatment Studies At The ASSH Annual Meeting 9/18/2014
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014
Galapagos NV (GLPG.BR) Reports High Participation Rate In Long Term Extension Study With GLPG0634 In RA Patients 9/18/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of RSV F-Protein Nanoparticle Vaccine Candidate In Healthy Third-Trimester Pregnant Women 9/17/2014
BioBlast Pharma (ORPN) Announces Preclinical And Clinical Pharmacokinetic Results With Cabaletta, Interim Safety Results From Phase 2/3 HOPEMD Study In OPMD 9/17/2014
Can-Fite BioPharma (CFBI)'s Drug CF101 Is Presented In Scientific Journal As One Of Four Small Molecule Drugs For The Treatment Of Psoriasis 9/17/2014
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014
Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows Positive Data In A Proof Of Concept Study 9/17/2014
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Successful Results For MOB-015 In A Phase II Study For The Treatment Of Onychomycosis 9/17/2014
Amarantus BioSciences, Inc. Provides Program Update On Phase 2b Eltoprazine For Parkinson's Disease And Adult ADHD 9/17/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Overall And KRAS-Mutated Patient Data From U.S. Randomized Phase 2 Pancreatic Cancer Study 9/17/2014
AVANIR Pharmaceuticals (AVNR) Rockets As Lead Drug Succeeds In Reducing Alzheimer's Related Agitation; Stock Up 63.20% At 10:19AM ET On Monday 9/16/2014
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9/16/2014
Thrasos Therapeutics Announces Successful Formal Interim Analysis And Clinical Update For Phase 2 Study Of THR-184 For Acute Kidney Injury 9/16/2014
Ophthotech Corporation (OPHT) Announces Fovista® Phase 2b Independent Analysis Shows That Fovista® Anti-PDGF Therapy, Combined With Anti-VEGF Therapy, Is Associated With A Reduction Of Sub-Retinal Fibrosis In Wet AMD Patients 9/16/2014
NovaBiotics Ltd Receives Orphan Drug Status From FDA For Lynovex® For The Treatment Of Cystic Fibrosis 9/16/2014
Ascendis Pharma A/S Announces Positive Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 9/16/2014
Coldstream Laboratories Inc. Partners With CytImmune Sciences Inc. For Phase 2 Sterile Manufacturing 9/16/2014
Anergis Reports Positive Long-Term Clinical Efficacy Of Lead Compound AllerT 9/16/2014
Cardioxyl Pharmaceuticals Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 9/16/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: Improved Survival Observed In Pediatric Patients With Severe Hypophosphatasia (HPP) Who Were Treated With Investigational Asfotase Alfa For Up To Five Years 9/15/2014
Cellprothera And BioCardia Partner On Phase 2 EXCELLENT Trial 9/15/2014
Lexicon Pharmaceuticals, Inc. (LXRX) Announces A Publication In The American Diabetes Association's Journal, Diabetes Care 9/12/2014
Amarantus BioSciences, Inc. Completes Enrollment Of 72 Patient LP-002 Clinical Study For Alzheimer's Blood Diagnostic Lympro Test® 9/12/2014
Genocea Biosciences Commences Phase 2a Trial For GEN-004, Universal Pneumococcal Vaccine Candidate 9/12/2014
Oxygen Biotherapeutics, Inc. (OXBT) Shares Gyrate After Halting Mid-Stage Brain Injury Trial 9/12/2014
Synthetic Biologics, Inc. (SYN) To Host Phase 2 Trimesta™ For Multiple Sclerosis Conference Call 9/11/2014
Prosonix Confirms The Potential Of Its Multi-Component Particle™ Technology For Developing Novel Inhaled Dual And Triple Combination Therapies For Respiratory Diseases 9/11/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled in Lucitanib Phase 2 Study In FGF-aberrant Advanced Breast Cancer 9/11/2014
Enanta Pharmaceuticals, Inc. Announces The Initiation Of Phase 2b Clinical Trial With Regimen Containing HCV Protease Inhibitor ABT-493 9/10/2014
Cellceutix (CTIX) Provides Initial Observations Of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application To FDA For Phase 2 Trial Of Brilacidin-OM For Oral Mucositis 9/10/2014
Symbiomix Therapeutics, LLC Makes First Corporate Announcement: Completion Of Enrollment In A Phase 2 Clinical Trial Of SYM-1219 For Bacterial Vaginosis 9/9/2014
AstraZeneca PLC (AZN)’s Phase 2 Lung Drug Data Gives Mixed Messages 9/9/2014
Serodus AS Announces Positive Phase Iia Results On SER100 In Patients With Systolic Hypertension 9/9/2014
Mimetogen Pharmaceuticals Announces Topline Results Of Its Second Clinical Study With MIM-D3 For The Treatment Of Dry Eye Syndrome 9/9/2014
Theravance, Inc. (THRX) Announces Positive Top-Line Results From Phase 2b Dose-Ranging Study Of Its Investigational LAMA, TD-4208, For The Treatment Of COPD 9/9/2014
C3 Jian, Inc. Completes Phase 2 Clinical Trial Of Anti-Cavity Drug 9/9/2014
Data On Chimerix, Inc. (CMRX)'s Brincidofovir Suggests Favorable Resistance Profile In Adenovirus And Cytomegalovirus (CMV) 9/9/2014
Seres Health Presents Final Data For Study Of SER-109 In Recurrent Clostridium Difficile Infection At ICAAC 2014 Conference 9/9/2014
Galena Biopharma  (GALE) Doses First Patient In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 9/9/2014
Scioderm To Present Data From Phase 2b Study Of Zorblisa™ (SD-101) At The Debra International Congress 9/9/2014
Advaxis, Inc. Provides A Clinical Development Update For Its Immunotherapy, ADXS-HPV, For The Treatment Of Cervical Cancer 9/9/2014
ASLAN Pharmaceuticals Pte Ltd Doses First Patients In First Clinical Study In Taiwan 9/9/2014
Amarantus BioSciences, Inc. Announces Positive MANF Ocular Toxicology Data 9/9/2014
Mast Therapeutics (MSTX) Reports Positive Results From Phase 2 Pulmonary Arterial Hypertension Study 9/8/2014
Recro Pharma (REPH) Halts Pain Drug Study Due To Fault In Trial Design; Stock Tanks 9/8/2014
ProSensa Holding N.V. (RNA) Announces Lancet Neurology Publication Of An Exploratory Phase 2 Study (DEMAND II) Demonstrating Efficacy And Safety Of Drisapersen In Patients With Duchenne Muscular Dystrophy 9/8/2014
Sangamo BioSciences, Inc. (SGMO) Announces Presentation At ICAAC Of New Clinical Data Demonstrating Sustained Functional Control Of Viremia In Multiple HIV-Infected Subjects Treated With SB-728-T 9/8/2014
GenSpera Presents Mipsagargin (G-202) HCC Clinical Trial Update At 8th International Liver Cancer Association Conference 9/8/2014
KemPharm, Inc. Advances KP201 Clinical Program With Initiation Of Human Abuse Liability And Human Gastrointestinal Motility Trials 9/8/2014
Pharmatech, Inc. Announces Research Collaboration Under Phase II National Cancer Institute/SBIR Grant With Weill Cornell Medical College 9/8/2014
European Medicines Agency Accepts TiGenix Pediatric Investigation Plan For Cx601 9/8/2014
Update On Invion Limited’s Phase II Study Of INV103 (Ala-Cpn10) In Lupus Patients 9/8/2014
PRANA Biotechnology (PRAN) Receives FDA Orphan Drug Designation For PBT2 For Huntington Disease 9/5/2014
SCRA Technology Ventures Company Publishes Phase 2 Clinical Trial Results 9/5/2014
TRACON Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial Of TRC105 In Patients With Soft Tissue Sarcoma 9/4/2014
Merck & Co., Inc. (MRK)’s Investigational Beta-Lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) And Fast Track Designations By FDA 9/4/2014
Kamada Ltd. (KMDA) Reports Final Results From Phase 2/3 Clinical Trial Of Inhaled Alpha-1 Antitrypsin To Treat Alpha-1 Antitrypsin Deficiency 9/4/2014
Alkermes plc (ALKS) Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic 9/3/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Phase 2 Trial - Successful Efficacy Results 9/3/2014
Nuvo Research Inc. (NRI.TO) Completes Enrollment In WF10™ Phase 2 Clinical Trial 9/3/2014
Edison Pharmaceuticals, Inc. Announces Phase 2 Positive Clinical Results For EPI-743 In Rett Syndrome 9/3/2014
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach To Treat Multiple Sclerosis 9/3/2014
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014
Arena Pharmaceuticals, Inc. (ARNA)' APD811 Granted Orphan Drug Status For Pulmonary Arterial Hypertension 9/3/2014
Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 9/3/2014
Oncolytics Biotech Inc. (ONC.TO) Neuroderm Announces Start Of Phase 2a Study Of Continuous Subcutaneous Liquid Levodopa/Carbidopa Administration For Patients With Severe Parkinson's Disease 9/3/2014
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Patient Enrollment In U.S. Randomized Phase 2 Ovarian Cancer Study 9/3/2014
AstraZeneca PLC (AZN) Pops On Possibility Of Another Pfizer (PFE) Bid; Start Of New Cancer Trial 9/2/2014
MediciNova, Inc. To Present Data On MN-001 (Tipelukast) For The Treatment Of Idiopathic Pulmonary Fibrosis (IPF) During The 18th International Colloquium On Lung And Airway Fibrosis (ICLAF) 9/2/2014
Conatus Pharmaceuticals Inc. Initiates Phase 2 Trial In Patients With Liver Cirrhosis And Separate Open Label Phase 2 Trial In Cirrhosis Patients With Portal Hypertension 9/2/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Adolescents With ADHD 9/2/2014
Cellular Biomedicine Group (CBMG) Launches Clinical Research Study For Cartilage Defect Stem Cell Therapy 9/2/2014
Nuvilex (NVLX) Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 9/2/2014
Promedior Receives U.S. Orphan Drug Designation For PRM-151 For The Treatment Of Myelofibrosis 9/2/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Completes Enrollment In Randomized Phase 2 Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 9/2/2014
VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted For Motolimod (VTX-2337), A Novel Immunotherapy For Women With Ovarian Cancer 9/2/2014
Xention Limited Commences First Phase 2 Study Of XEN-D0103 In Atrial Fibrillation 9/2/2014
Dezima Pharma Reports Positive Results In Its Phase 2b TULIP Trial With CETP Inhibitor TA-8995 In Dyslipidemia 8/29/2014
Repros Therapeutics Inc. (RPRX)'s Testosterone Drug Found Superior To AbbVie (ABBV)'s Androgel In Study 8/28/2014
Pfizer Inc. (PFE)’s Investigational Vaccine Candidate For Clostridium Difficile Receives FDA Fast Track Designation 8/28/2014
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce Initiation Of Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 8/28/2014
Madison Vaccines To Be Used In Clinical Trial Of A New Combination Approach To Immunotherapy Funded By The Prostate Cancer Foundation And The Movember Foundation 8/28/2014
Auxilium Pharmaceuticals (AUXL) To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 8/28/2014
Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury 8/27/2014
ERYtech Pharma Announces Second Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 8/27/2014
Gilead Sciences, Inc. (GILD) Shaky As Achillion Pharmaceuticals, Inc. (ACHN)'s Hepatitis C Drug Cures All Patients In Mid-Stage Trial 8/27/2014
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase 2 Study Of AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 8/26/2014
Ruthigen Receives Recommendation From Data Monitoring Committee To Initiate Phase 1/2 Human Clinical Trial Of RUT58-60 8/26/2014
Profil Institute for Clinical Research, Inc. Reaches Milestone In Early Phase Clinical Research For Diabetes 8/26/2014
Anavex Life Sciences Corp. (AVXL.OB) Selects The Alfred Hospital In Melbourne, Australia As Lead Site For Phase 2a Alzheimer's Clinical Trial 8/26/2014
U.S. Army Funds Phase 2 Clinical Trial At University of California, Los Angeles (UCLA) For The Treatment Of PTSD With The NeuroSigma, Inc. eTNS System 8/25/2014
Pradaxa® (dabigatran etexilate mesylate) Data To Be Presented At European Society of Cardiology Congress 2014 8/25/2014
Look Out Auxilium Pharmaceuticals (AUXL), BioSpecifics Technologies Corporation (BSTC) Also Touts Positive Data From Phase 2a Study Of CCH For Cellulite 8/22/2014
Auxilium Pharmaceuticals (AUXL) Drug Found Effective Against Cellulite In Phase 2 Study 8/22/2014
NovaBay Pharmaceuticals, Inc. (NBY) Reports NVC-422 Missed Endpoints In Phase 2 Study 8/21/2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type 2 Diabetes In Phase IIb Study On BTI-320 In The U.S. 8/20/2014
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014
MediciNova, Inc. Shows Off Positive Phase 2a Study Of Ibudilast 8/19/2014
iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results 8/19/2014
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
Celator Pharmaceuticals, Inc. Initiates Pharmacokinetic And Pharmacodynamics Clinical Study Of CPX-351 8/19/2014
DelMar Pharmaceuticals Provides Update On Glioblastoma Clinical Trial And Results Of Warrant Tender Offer 8/19/2014
Innate Immunotherapeutics’s Phase 2B Clinical Trial On SPMS To Start Recruiting Patients Following Perth Site Obtaining Ethics Approval 8/19/2014
Blanchette Rockefeller Neurosciences Institute Release: Human Brain Deficits Of PKCe: Targeted For Alzheimer's Disease Therapeutic And Diagnostic Trials 8/18/2014
Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc. 8/18/2014
Egalet Announces Successful End-Of-Phase 2 Meeting With The FDA For Egalet-002 8/18/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Publication By KaloBios Pharmaceuticals, Inc. (KBIO) And Collaborators Shows EphA3 As Target For Highly Selective Anticancer Therapy 8/14/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study 8/14/2014
Intercept Pharmaceuticals (ICPT) Soars As Liver Drug Found Effective In Mid-Stage Trial 8/13/2014
Ohr Pharmaceutical (OHRP) Announces Additional Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data In Wet-AMD; The IMPACT Study 8/13/2014
Cellular Biomedicine Group (CBMG) Completes Patient Treatment In Phase 2b Clinical Trial For Rejoin™ Therapy For Knee Osteoarthritis 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Esperion Therapeutics, Inc. (ESPR) Provides Etc-1002 Development Program Update; Reports Second Quarter 2014 Financial Results 8/12/2014
Biodel Inc. (BIOD)'s Insulin Drug Found Effective In Phase 2 Trial 8/11/2014
Ohr Pharmaceutical (OHRP) Announces Squalamine Eye Drop (OHR-102) Phase 2 Clinical Data in Retinal Vein Occlusion 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Mirati Therapeutics  (MRTX) Receives Orphan Designation From U.S. FDA For Mocetinostat In Diffuse Large B-Cell Lymphoma 8/11/2014
Celladon Corporation Announces Trial To Investigate MYDICAR In Patients With Heart Failure And LVAD 8/11/2014
Xenetic Biosciences Announces Ongoing Safety And Efficacy Data From Phase 2 Trial Of Erepoxen(R) 8/11/2014
BioSpecifics Technologies Corporation (BSTC) Announces Initiation Of Phase 2 Clinical Study Of CCH For Treatment Of Lipoma 8/8/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Oral Presentation Of CytRx Corporation (CYTR)’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology 8/7/2014
Symphogen A/S Release: Sym004 Advances Into Two New Clinical Trials And Receives Milestone Payments 8/7/2014
Neurovance Completes Enrollment In Human Abuse Liability Study For Centanafadine (Formerly Called EB-1020) For Adult ADHD 8/7/2014
San Diego's Cytori Therapeutics, Inc. (CYTX) Crashes As Safety Concerns Suspend Athena Trials 8/7/2014
Egalet Announces Topline Results From Bioequivalence Studies of Abuse-Deterrent Morphine, Egalet-001 8/6/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Cara Therapeutics, Inc. (CARA) Initiates Proof-Of-Concept Phase 2 Trial Of I.V. CR845 In Uremic Pruritus 8/6/2014
Synthetic Biologics, Inc. (SYN) On Track To Initiate Clinical Program For SYN-004 To Protect Against C. difficile 8/5/2014
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014
Ophthotech Corporation (OPHT) Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration 8/5/2014
Velocity Pharmaceutical Development, LLC And Tigercat Pharma, Inc. Announce First Patient Dosed In Phase 2 Study Of VPD-737 In Prurigo Nodularis 8/4/2014
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014
Final Patient Treated In NeuralStem Inc. Phase II ALS Stem Cell Trial 8/4/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies 8/4/2014
NPS Pharmaceuticals, Inc. (NPSP) Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH) 8/4/2014
Novartis AG (NVS) Malaria Pill KAE609 Shows Promise As Best Drugs Fail 8/1/2014
Biota Pharmaceuticals, Inc. (BOTA) Stock Crashes As Influenza Drug Laninamivir Octanoate Fails Mid-Stage Trial; Stock Down -20.54% At 11:37AM ET 8/1/2014
CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV 7/31/2014
Expanded Data On Disability And Cognitive Improvements In Phase 2 Study Of Synthetic Biologics, Inc. (SYN)' Trimesta™ In Multiple Sclerosis To Be Presented At 2014 Joint ACTRIMS-ECTRIMS Meeting 7/31/2014
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014
Kala Pharmaceuticals Initiates Phase 2 Clinical Trial To Evaluate LE-MPP (KPI-121) In Patients With Retinal Vein Occlusion And Diabetic Macular Edema 7/31/2014
Immune Pharmaceuticals, Inc. Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 7/30/2014
RXi Pharmaceuticals (RXII) Expands Clinical Program With Initiation Of Third Phase 2a Study With RXI-109 For Treatment Of Hypertrophic Scars 7/30/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002 7/29/2014
EMD Serono Initiates Phase 2 Study Of Anti-PD-L1 Antibody MSB0010718C In Metastatic Merkel Cell Carcinoma 7/29/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
Neurotrope Initiates Phase 2a Study Of Bryostatin For The Treatment Of Alzheimer's Disease - Doses First Patients 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
Medivir AB (MVRBF): Phase II COSMOS Study Results Published In Lancet On World Hepatitis Day 7/28/2014
Phase 2 COSMOS Study Results Published In The Lancet Demonstrate Efficacy And Safety Of Janssen’s Once-Daily Simeprevir In All Oral 12-Week Combination With Sofosbuvir For Genotype 1 Chronic Hepatitis C 7/28/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase II Study Of ERY-ASP In Pancreatic Cancer 7/28/2014
Quark Pharmaceuticals Inc. Reports Favorable Results From Phase 2 Clinical Trial Evaluating Investigational Sirna QPI-1002 7/28/2014
Esperion Therapeutics, Inc. (ESPR) Announces Initiation Of A Phase 2 Clinical Study Of ETC-1002 In Patients With Hypercholesterolemia And Hypertension 7/24/2014
Alios BioPharma Reports Positive Results Of Its Anti-RSV Nucleoside Analog AL-8176 In A Phase 2 Challenge Study In Adults Infected With Respiratory Syncytial Virus (RSV) 7/24/2014
Celsion Corporation (CLSN) Announces Positive Interim Data Update From Its Phase 2 DIGNITY Study In Breast Cancer 7/24/2014
Innapharma: Completion Of Target Enrollment In The Phase 2 EffiKIR Trial 7/24/2014
Inovio Pharmaceuticals (INO) HPV Immunotherapy Achieves Primary Efficacy Endpoint In Randomized Phase 2 Cervical Dysplasia Trial 7/23/2014
Aduro Biotech Receives Breakthrough Therapy Designation From FDA For Innovative Pancreatic Cancer Combination Immunotherapy 7/23/2014
Biotron Limited (BIT:AU) BIT225 Reverses HIV-Induced Impairment Of The Immune System 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
Advaxis, Inc. And MedImmune (AZN) Partner On Immuno-Oncology Combination Clinical Trial 7/22/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
Halozyme Therapeutics, Inc. (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Genocea Biosciences Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy 7/21/2014
CASI Pharmaceuticals  (ENMD) Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With Enmd-2076 For Triple-Negative Breast Cancer In China 7/21/2014
AVANIR Pharmaceuticals (AVNR) Announces FDA Acceptance Of IND For AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 7/21/2014



//-->